All In Biotech

Drug Trial Radar · NCT00262080

Efficacy and Safety Study of DX-88 to Treat Acute Attacks of Hereditary Angioedema (HAE)

A Double-blind, Placebo-controlled Study (72 Patients, Randomized 1:1) Followed by a Repeat-dosing Phase to Assess the Efficacy and Safety of DX-88 (Ecallantide; Recombinant Plasma Kallikrein Inhibitor) for the Treatment of Acute Attacks of Hereditary Angioedema

Last checked: Nov 20, 2026Latest source record: Jun 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

91

Actual

Start

Dec 31, 2005

Primary completion

Dec 31, 2005

Study completion Feb 28, 2007

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Dec 6, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if a subcutaneous dose of DX-88 (ecallantide; an investigational product) is safe and relieves symptoms of HAE in patients suffering from moderate to severe acute attacks of HAE.

Conditions

  • Hereditary Angioedema (HAE)

Interventions

  • ecallantideDrug

    dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.

  • Phosphate Buffer Saline (PBS),Drug

    given as three 1mL subcutaneous injections.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment Outcome Score at 4 Hours Post-DoseTime frame: 4 hours post-dose (DOUBLE-BLIND PART)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute for Asthma and Allergy

    Wheaton, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.